Lifeloc Technologies, INC 10-Q quarterly reports

Lifeloc Technologies reported a 1% increase in Q1 2026 revenue to $2.29 million, with a narrowed net loss of $152,713, driven by improved gross profit margins.

Lifeloc Technologies reports increased net losses for Q3 and the nine months ended September 30, 2025, driven by higher operating expenses and interest costs, despite modest revenue growth, as it invests heavily in its SpinDetect drug analysis system and pursues a merger with ELST.

Lifeloc Technologies reported increased net losses for Q2 and the first half of 2025, driven by declining product sales and higher interest expenses, despite ongoing investment in its SpinDx drug detection technology.

Lifeloc Technologies saw a 6% increase in product sales for Q1 2025 compared to Q1 2024, while continuing development of its SpinDx drug detection technology.

Lifeloc Technologies experienced a decrease in revenue and a net loss in Q3 2024, primarily due to reduced product sales and increased research and development expenses.

Lifeloc Technologies experienced a net loss in Q2 2024 due to increased research and development expenses, despite a slight increase in product sales.

LifeLoc Technologies experienced a net loss in Q1 2024, despite relatively stable revenues, due to increased research and development and sales and marketing expenses.